NCT00765102 · REGISTRY CONDITION SEARCH

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2019-11-25

This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomib non-resistant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Count of Participant Best Overall Response As Assessed by the Investigator

→

outcome · POSTED

Participants With Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)

→

outcome · POSTED

Maximum Observed Concentration (Cmax)

→

outcome · POSTED

Time to Maximum Observed Concentration (Tmax)

→

outcome · POSTED

Terminal Half-life (t1/2)

→

outcome · POSTED

Total Clearance (CL)

→

outcome · POSTED

Total Volume of Distribution (Vz)

→

outcome · POSTED

Kaplan Meier Estimate for Time to Progression Assessed by the Investigator

→

outcome · POSTED

Kaplan Meier Estimate for Time to Response Assessed by the Investigator

→

outcome · POSTED

Kaplan Meier Estimate for Duration of Response Assessed by the Investigator

→

outcome · POSTED

Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator

→

outcome · POSTED

Kaplan Meier Estimates for Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria Patients must fulfill all of the following criteria to be eligible for study participation: * Male or female patients aged ≥ 18 years old * Has given voluntary written informed consent before any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care * Previously diagnosed with multiple myeloma (MM) based on standard criteria as follows: * Major criteria: 1. Plasmacytomas on tissue biopsy. 2. Bone marrow plasmacytosis (\>30% plasma cells). 3. Monoclonal immunoglobulin spike on serum electrophoresis IgG \>3.5 g/dL or IgA \>2.0 g/dL; kappa or lambda light chain excretion \>1 g/day on 24 hour urine protein electrophoresis * Minor criteria: 1. Bone marrow plasmacytosis (10 to 30% plasma cells) 2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria 3. Lytic bone lesions. 4. Normal IgM \<50 mg/dL, IgA \<100 mg/dL or IgG \<600 mg/dL Any of the following sets of criteria will confirm the diagnosis of MM: * Any two of the major criteria * Major criterion 1 plus minor criterion 2, 3, or 4. * Major criterion 3 plus minor criterion 1 or 3. * Minor criteria 1, 2, and 3 or 1, 2, and 4. * Currently has MM with: o Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of \>=1 gm/dL and/or urine monoclonal immunoglobulin spike of \>=200 mg/24 hours, or evidence of lytic bone disease * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Life-expectancy \> 3 months * All women of childbearing potential must use an effective barrier method of contraception. Male patients should use a barrier method of contraception during the treatment period and for 3 months thereafter * Patients must meet the following laboratory criteria at Baseline (Day 1 of Cycle 1, before study drug administration): * Platelet count ≥ 100\*10\^9/L * Absolute neutrophil count ≥ 1.5\*10\^9/L * OR if the bone marrow is extensively infiltrated * Platelet count ≥ 75\*10\^9/L * Absolute neutrophil count ≥ 1.0\*10\^9/L * Patients must meet the following laboratory criteria at the Screening visit conducted within 14 days of enrollment (Day 1, Cycle 1): * o Aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 3.0\*upper limit of normal (ULN) * Serum bilirubin ≤ 2.0\*ULN * Calculated or measured creatinine clearance: ≥30 mL/minute. Patient with a creatinine \>10mL/min and \<30 mL/min due to significant myelomatous involvement of the kidneys may be enrolled in the study after receipt of approval from the lead investigator and sponsor * Serum potassium ≥ 3.8 mmol/L * Serum magnesium \>1.8 mg/dL * Serum phosphorus ≥ lower limit of normal (LLN) Exclusion Criteria Patients are ineligible for entry if any of the following criteria are met: * Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or thalidomide, lenalidomide, arsenic trioxide, bortezomib, or glucocorticosteroids within 3 weeks prior to the first dose of romidepsin * Prior major surgery within 3 weeks prior to the first day of treatment * Use of any investigational agent within 4 weeks of study entry * Prior therapy with romidepsin * Any known cardiac abnormalities such as: * Congenital long QT syndrome; * QTc interval ≥ 500 milliseconds; * Myocardial infarction within 6 months of Day 1. Subjects with a history of myocardial infarction between 6 and 12 months prior to the first day of cycle one who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate; * Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min); * Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present; * An ECG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present; * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction \<40% by Multi Gated Acquisition Scan (MUGA scan) or \<50% by echocardiogram and/or MRI; * A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD); * Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes; * Uncontrolled hypertension, i.e., blood pressure (BP) of ≥160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or * Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers) * POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) * Plasma cell leukemia * Primary amyloidosis * Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) * Severe hypercalcemia, i.e., serum calcium ≥14 mg/dL (3.5 mmol/L) * Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Other concurrent severe and/or uncontrolled medical or psychiatric conditions. * Concomitant use of drugs that may cause a prolongation of the QTc * Concomitant use of CYP3A4 inhibitors * Patients who have hypersensitivity to bortezomib, boron or mannitol * Patients who are pregnant or breast-feeding * Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period. Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.
intervention Names
Drug: Bortezomib
Drug: Romidepsin
label
Romidepsin + Bortezomib
type
EXPERIMENTAL

interventions

arm Group Labels
Romidepsin + Bortezomib
description
Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion. Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.
name
Bortezomib
other Names
VELCADE®
type
DRUG
arm Group Labels
Romidepsin + Bortezomib
description
Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
name
Romidepsin
other Names
ISTODAX®
depsipeptide
FK228
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 32
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Complete Response: disappearance of monoclonal protein from blood and urine, and disappearance of soft tissue plasmacytomas, \<5% plasmas cells in marrow and no increase of lytic bone lesions. Very Good Partial Response: disappearance of plasmacytomas, no increase of lytic bone lesions, serum and urine M-protein not detectable by immunofixation, other. Partial Response: \>=50% decrease in serum monoclonal protein, and in soft tissue plasmacytomas, no increase of lytic bone lesions, other. Minimal Response (MR): ≥ 25% to ≤ 49% decrease in serum monoclonal protein, and in size of plasmacytomas, no increase of lytic bone lesions, other. Stable Disease: Less than MR, but not PD Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia.
measure
Count of Participant Best Overall Response As Assessed by the Investigator
time Frame
up to 8 months

secondary Outcomes

description
Counts of participants with TEAEs, and subset by relation to drug, grade of severity, serious, TEAEs leading to discontinuation or leading to death. AEs were graded for severity according to the National Cancer Institute Common Terminology Criteria (NCI CTCAE), V 3.0: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe (prevents normal everyday activities); Grade 4: Life-threatening or disabling; Grade 5: Death.
measure
Participants With Treatment-emergent Adverse Events (TEAEs)
time Frame
up to 9 months
description
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) of Romidepsin based on plasma samples.
measure
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)
time Frame
Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
description
Maximum observed concentration of Romidepsin
measure
Maximum Observed Concentration (Cmax)
time Frame
Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
description
Time to maximum observed concentration of Romidepsin
measure
Time to Maximum Observed Concentration (Tmax)
time Frame
Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
description
Terminal half-life of Romidepsin
measure
Terminal Half-life (t1/2)
time Frame
Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
description
Total clearance of Romidepsin
measure
Total Clearance (CL)
time Frame
Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
description
Total volume of distribution of Romidepsin
measure
Total Volume of Distribution (Vz)
time Frame
Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion
description
Time to progression of disease is defined as the time from initiation of therapy to progressive disease as assessed by the investigator. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia.
measure
Kaplan Meier Estimate for Time to Progression Assessed by the Investigator
time Frame
up to month 8
description
The time to the first response is defined as the time from the initiation of therapy to the first evidence of a confirmed response (complete response, very good partial response, partial response or minimal response). Complete Response: disappearance of monoclonal protein from blood and urine, and disappearance of soft tissue plasmacytomas, \<5% plasmas cells in marrow and no increase of lytic bone lesions. Very Good Partial Response: disappearance of plasmacytomas, no increase of lytic bone lesions, serum and urine M-protein not detectable by immunofixation, other. Partial Response: \>=50% decrease in serum monoclonal protein, and in soft tissue plasmacytomas, no increase of lytic bone lesions, other. Minimal Response (MR): ≥ 25% to ≤ 49% decrease in serum monoclonal protein, and in size of plasmacytomas, no increase of lytic bone lesions, other.
measure
Kaplan Meier Estimate for Time to Response Assessed by the Investigator
time Frame
up to month 8
description
Duration of response is defined as the time from first response to progressive disease as assessed by the investigator. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia.
measure
Kaplan Meier Estimate for Duration of Response Assessed by the Investigator
time Frame
up to month 8
description
Progression-free survival is the time from initiation of therapy to progressive disease, removal from study for any reason, death from any cause, or the last follow-up visit, whichever occurs first. Progressive Disease(PD):\>25% increase in serum monoclonal paraprotein, or \>25% plasma cells in marrow, or \>25% increase in 24-hour urinary light chain excretion or increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, or hypercalcemia. Disease progression for participants relapsing from a complete response: reappearance of serum or urinary paraprotein on imunofixation, \>= 5% plasma cells in the bone marrow aspirate or biopsy, increase in existing lytic bone lesions or soft tissue plasmacytomas or new bone lesions or soft tissue plasmacytomas, development of hypercalcemia.
measure
Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator
time Frame
up to month 8
description
Overall survival is the time from initiation of therapy to death from any cause.
measure
Kaplan Meier Estimates for Overall Survival
time Frame
up to month 8

Full study description

brief Summary: This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomib non-resistant.

Source references

references

citation
Berenson J, et al. A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. Presented at 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orlando FL. Abstract No. e10908. J Clin Oncol 2009;27(15s)
type
BACKGROUND

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f99fc1bc6f7cb1f2da71
requested nct id
NCT00765102
primary nct id
NCT00765102
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
e82cfabac0b32f05219d46a33a5f6ced3a6e7f742fa8cb302bbc12b69d138ad6
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f99fc1bc6f7cb1f2da71
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00765102
occurrences
context exact
NCT00765102
end
11
exact text
NCT00765102
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/699/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
7ae6ae4b2cae4a89af1f87c7fee7d7e1143d5f804c4f452fe9dc23897ff4721b
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice